TRMED Fundamental Analysis - THOR MEDICAL ASA

Fundamental Rating

TRMED gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. While TRMED seems to be doing ok healthwise, there are quite some concerns on its profitability. TRMED is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TRMED has reported negative net income.

In the past year TRMED has reported a negative cash flow from operations.

TRMED had negative earnings in each of the past 5 years.

In the past 5 years TRMED always reported negative operating cash flow.

1.2 Ratios

TRMED has a better Return On Assets (-8.30%) than 61.64% of its industry peers.

TRMED has a better Return On Equity (-10.22%) than 65.75% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.3%
ROE	-10.22%
ROIC	N/A

ROA(3y)-146.91%

ROA(5y)-131.48%

ROE(3y)-270.57%

ROE(5y)-231.37%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TRMED so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TRMED has more shares outstanding than it did 1 year ago.

The number of shares outstanding for TRMED has been increased compared to 5 years ago.

The debt/assets ratio for TRMED is higher compared to a year ago.

2.2 Solvency

TRMED has an Altman-Z score of 8.15. This indicates that TRMED is financially healthy and has little risk of bankruptcy at the moment.

TRMED's Altman-Z score of 8.15 is amongst the best of the industry. TRMED outperforms 90.41% of its industry peers.

TRMED has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.00, TRMED belongs to the top of the industry, outperforming 95.89% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	8.15

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 6.48 indicates that TRMED has no problem at all paying its short term obligations.

With an excellent Current ratio value of 6.48, TRMED belongs to the best of the industry, outperforming 87.67% of the companies in the same industry.

TRMED has a Quick Ratio of 6.48. This indicates that TRMED is financially healthy and has no problem in meeting its short term obligations.

TRMED's Quick ratio of 6.48 is amongst the best of the industry. TRMED outperforms 87.67% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.48
Quick Ratio	6.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.44% over the past year.

EPS 1Y (TTM)94.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%74.77%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y50.51%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRMED. In the last year negative earnings were reported.

Also next year TRMED is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TRMED does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THOR MEDICAL ASA

OSL:TRMED (5/30/2025, 7:00:00 PM)

2.37

0 (-0.21%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-28 2024-02-28/amc

Earnings (Next)N/A N/A

Inst Owners0.78%

Inst Owner ChangeN/A

Ins Owners2.16%

Ins Owner ChangeN/A

Market Cap745.15M

Analysts34.29

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.87
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)-0.5

Fwd EYN/A

FCF(TTM)-0.09

FCFYN/A

OCF(TTM)-0.09

OCFYN/A

SpS0

BVpS0.83

TBVpS-0.08

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.3%
ROE	-10.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-146.91%

ROA(5y)-131.48%

ROE(3y)-270.57%

ROE(5y)-231.37%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.48
Quick Ratio	6.48
Altman-Z	8.15

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)94.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%74.77%

EPS Next Y50.51%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y97.72%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year51.22%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y92.99%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y92.99%

OCF growth 3YN/A

OCF growth 5YN/A

THOR MEDICAL ASA (TRMED.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens